NovoLog is also available in pen injector formats. Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris ...

The agency has given a thumbs up to Sanofi’s Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk’s NovoLog for patients ... provided by prefilled pen in a 3 mL dose or ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Novo Nordisk is a dominant force in the Novolin N market, known for its commitment to innovation and excellence in diabetes care. 1: Vials, Pen Devices, Type 1 Diabetes, Type 2 Channel ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls the new drug “Merilog,” a biosimilar to the widely-used insulin product ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin ... patient-use prefilled pen and a 10-mL multiple-dose ...

Merilog has been approved as biosimilar to Novolog (insulin aspart ... for both a 3 milliliter or mL single-patient-use prefilled pen and a 10 mL multiple-dose vial. As a rapid-acting human ...